WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription. “While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free. The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS. |
Adzija, Kosta guide Boston to 2Stephenson hits 1st career grand slam, Fairchild drives in 2 as the Reds beat the Angels 7Patti Smith reacts to Taylor Swift nameBritain's Got Talent winnersLee's single in eighth ends noUN calls for more support as gang violence escalates in HaitiResidents of four SerbPortland downs Dash 4Arturas Karnisovas vows to make changes after the Bulls missed playoffs for 2nd straight seasonWhatsApp launches a major change that makes it much faster to find chats